Skip to main content

Table 2 Baseline clinicopathological characteristics of patients

From: Prognostic significance of branched-chain amino acid transferase 1 and CD133 in triple-negative breast cancer

Clinicopahtological criteria

No. of patients

Patients with recurrence n = 82

Patients without recurrence n = 209

P

Age at diagnosis

   

0.602

 ≤ 49

154

41 (50.00%)

113 (54.07%)

 

 > 49

137

41 (50.00%)

96 (45.93%)

 

Menopausal status

   

0.897

 Pre-menopause

148

41 (50.00%)

107 (51.2%)

 

 Post-menopause

143

41 (50.00%)

102 (48.8%)

 

Histological grade

   

0.393

 I/II

85

27 (32.93%)

58 (27.75%)

 

 III

206

55 (67.07%)

151 (72.25%)

 

Tumor size

   

0.015

 pT1

136

31 (37.80%)

105 (50.24%)

 

 pT2

139

42 (51.22%)

97 (46.41%)

 

 pT3

12

8 (9.76%)

4 (1.91%)

 

 pT4

4

1 (1.22%)

3 (1.44%)

 

Nodal status

   

0.000

 negative

165

34 (41.46%)

131 (62.68%)

 

 1–3 nodes

63

15 (18.29%)

48 (22.97%)

 

 4–9 nodes

27

10 (12.2%)

17 (8.13%)

 

 ≥ 10 nodes

36

23 (28.05%)

13 (6.22%)

 

Stage

   

0.000

 I

92

15 (18.29%)

77 (36.84%)

 

 II

134

33 (40.24%)

101 (48.33%)

 

 III

65

34 (41.37%)

31 (14.83%)

 

Basal-like phenotype

   

0.850

 Negative

40

12 (14.63%)

28 (13.4%)

 

 Positive

251

70 (85.37%)

181 (86.6%)

 

Ki67 indexa

   

0.030

 ≤ 14

30

14 (17.07%)

16 (7.66%)

 

 > 14

261

68 (82.93%)

193 (92.34%)

 

TIL

   

0.002

 Low

153

55 (67.07%)

98 (46.89%)

 

 High

138

27 (32.93%)

111 (53.11%)

 

Family History

   

1.000

 Negative

275

78 (95.12%)

197 (94.26%)

 

 Positive

16

4 (4.88%)

12 (5.74%)

 

Chemotherapy

   

0.297

 Negative

32

6 (7.32%)

26 (12.44%)

 

 Positive

259

76 (92.68%)

183 (87.56%)

 

Radiotherapy

   

0.016

 Negative

179

41 (50.00%)

138 (66.03%)

 

 Positive

112

41 (50.00%)

71 (33.97%)

 

LVI

   

0.188

 Negative

270

74 (90.23%)

196 (93.78%)

 

 Positive

21

8 (9.77%)

13 (6.22%)

 

CD133

   

0.002

 H score (mean ± SE)

 

98.85 ± 8.534

68.74 ± 4.039

 

 Low expression

174

37 (45.12%)

137 (65.55%)

 

 High expression

117

45 (54.88%)

72 (34.45%)

 

BCAT1

   

0.000

 H score (mean ± SE)

 

101.46 ± 7.259

72.80 ± 3.758

 

 Low expression

205

44 (53.66%)

161 (77.03%)

 

 High expression

86

38 (46.34%)

48 (22.97%)

 
  1. TIL tumor infiltrating lymphocytes, LVI lymphovascular invasion, SE standard error. aKi-67 index threshold of 14% was chosen according to the St. Gallen Consensus 2013
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us